All In Biotech

Drug Trial Radar · NCT06015841

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

An Adaptive, Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamic Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 24, 2023

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
AC Immune SAIndustry
Sponsor type
Industry
Collaborators
ICON Clinical Research
First posted
Aug 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.

Conditions

  • Parkinson Disease
  • Parkinson Disease 6, Early-Onset

Interventions

  • PlaceboBiological

    The placebo is a solution matching the study treatment formulation.

  • ACI-7104.056 at Dose ABiological

    The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

  • ACI-7104.056 at Dose B (optional)Biological

    The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

  • ACI-7104.056 at Dose C (optional)Biological

    The study treatment (ACI-7104.056) consists of an adjuvanted protein peptide conjugate vaccine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs) assessed by intensity (mild, moderate or severe) and causal relationship (unrelated, or unlikely, possibly, probably or definitely related)Time frame: From Screening (ICF signature) to Week 100 in study part 1 and 2, and from Rescreening (ICF signature) to Week 78 in the extension phase
  2. Number of participants with abnormal MRI resultsTime frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
  3. Number of participants with clinically significant changes in physical and neurological examination resultsTime frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
  4. Number of participants reporting suicidal ideation or behavior using Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase
  5. Measurement of levels of specific antibodies against a-synuclein present in serum generated by ACI-7104.056Time frame: From Baseline to Week 100 in study part 1 and 2, and from Baseline to Week 78 in the extension phase

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Katholisches Klinikum Bochum GmbH

    Bochum, Germany

  • Paracelsus-Kliniken Deutschland GmbH & Co. KGaA

    Kassel, Germany

  • University Medical Centre Schleswig-Holstein

    Kiel, Germany

  • Hospital De La Santa Creu I Sant Pau

    Barcelona, Spain

  • Hospital Universitari Vall D Hebron

    Barcelona, Spain

  • Policlinica Gipuzkoa

    Donostia / San Sebastian, Spain

  • Hospital Universitario De La Princesa

    Madrid, Spain

  • Hospital Universitario Puerta De Hierro De Majadahonda

    Majadahonda, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Spain

  • King's College Hospital NHS Foundation Trust

    London, United Kingdom

  • Re:Cognition Health Limited

    London, United Kingdom

  • Northern Care Alliance NHS Foundation Trust

    Salford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.